专利检索 cpc:"A61K38/06" 第 4 页

31.

发明申请
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS 审中-公开

公开(公告)号：US20180251518A1

公开(公告)日：2018-09-06

申请号：US15971799

申请日：2018-05-04

申请人： IMMATICS BIOTECHNOLOGIES GMBH

发明人： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN

IPC分类号： C07K14/74 , A61K39/00 , C12N5/0783 , C07K14/47 , G01N33/569 , C12N9/64 , C07K14/00 , G01N33/50 , A61K38/17 , C07K16/28 , A61K45/06 , C07K14/725 , C12Q1/6886 , C07K16/30 , C07K7/06 , C07K7/02 , A61K38/08 , G01N33/566 , C07K16/18

CPC分类号： C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

32.

发明申请
COMPOSITIONS OF BIOACTIVE FULVATE FRACTIONS AND USES THEREOF 审中-公开

公开(公告)号：US20180250250A1

公开(公告)日：2018-09-06

申请号：US15812855

申请日：2017-11-14

申请人： OMNI BIOCEUTICAL INNOVATIONS, INC.

发明人： Gary W. Black , Jane Christensen , Farhan Taghizadeh

IPC分类号： A61K31/194 , A61K45/06 , A61K9/00

CPC分类号： A61K31/194 , A61K8/36 , A61K8/64 , A61K8/965 , A61K9/0014 , A61K31/352 , A61K35/10 , A61K45/06 , A61K2800/91 , A61K2800/92 , A61Q19/00 , A61Q19/08 , A61K2300/00 , A61K38/18 , A61K38/06

摘要： Compositions with fulvate fractions alone or in combination with growth factors, bioactive fragmented peptides, or combinations thereof are disclosed herein. Also disclosed are methods of using said compositions for the catalyzing cellular regeneration, including the healing, treatment, or prevention of skin disorders. Also disclosed are methods for extracting, isolating, and purifying fulvate fractions for use in the manufacture of said compositions.

33.

发明授权
Peptides and combination of peptides for use in immunotherapy against various tumors 有权

公开(公告)号：US10059755B2

公开(公告)日：2018-08-28

申请号：US15789731

申请日：2017-10-20

申请人： IMMATICS BIOTECHNOLOGIES GMBH

发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann

IPC分类号： C07K14/70 , C07K14/74 , C12N5/0783 , G01N33/569 , C07K16/28 , A61K45/06 , C07K14/725 , A61K39/00 , C12Q1/6886 , C07K16/30 , C07K14/47 , C07K7/06 , C07K7/02 , A61K38/08 , G01N33/566 , C07K16/18 , C12N9/64

CPC分类号： C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10

摘要： A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

34.

发明申请
HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF 审中-公开

公开(公告)号：US20180236112A1

公开(公告)日：2018-08-23

申请号：US15888634

申请日：2018-02-05

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： MARTIN G. POMPER , SANGEETA RAY , RONNIE C. MEASE , HASSAN SHALLAL

IPC分类号： A61K51/08 , C07D249/04 , C07K5/02 , C07K5/097

CPC分类号： A61K51/088 , A61K38/00 , A61K38/06 , A61K45/06 , A61K51/0482 , C07D249/04 , C07K5/0217 , C07K5/06086 , C07K5/0815 , C07K5/0821

摘要： The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (α-, ε-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.

35.

发明申请
METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY 审中-公开

公开(公告)号：US20180228864A1

公开(公告)日：2018-08-16

申请号：US15716644

申请日：2017-09-27

申请人： Stealth BioTherapeutics Corp

发明人： Kenneth Borow , D. Travis Wilson

IPC分类号： A61K38/07 , A61K45/06

CPC分类号： A61K38/07 , A61K38/06 , A61K38/166 , A61K38/1709 , A61K38/49 , A61K45/06 , A61K2300/00

摘要： This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).

36.

发明申请
COMPOSITION FOR TREATMENT OF RSV 审中-公开

公开(公告)号：US20180193404A1

公开(公告)日：2018-07-12

申请号：US15746382

申请日：2017-01-26

申请人： Emory University , YOUR ENERGY SYSTEMS, LLC

发明人： Lou Ann BROWN , Frederick Timothy GUILFORD

IPC分类号： A61K38/06 , A61K33/04 , A61K9/127 , A61P31/14

CPC分类号： A61K38/063 , A61K9/127 , A61K33/04 , A61K38/06 , A61K2300/00 , A61P31/14

摘要： This invention relates to a composition, the use of a composition for treatment, and a method of treatment of infection with Respiratory syncytial virus (RSV). The composition for treatment is a liposomally formulated reduced glutathione in a therapeutically effective amount to decrease the growth of respiratory syncytial virus. An oral preparation of liposomal reduced glutathione and a powdered form that can be reconstituted with sterile water or saline for intravenous administration are described.

37.

发明申请
Derivatives of Sulfated Polysaccharides, Method of Preparation, Modification and Use Thereof 有权

公开(公告)号：US20180171034A1

公开(公告)日：2018-06-21

申请号：US15737443

申请日：2016-06-24

申请人： Contipro a.s.

发明人： Tomas Bobula , Radovan Buffa , Hana Vagnerova , Romana Sulakova , Lucie Wolfova , Lenka Kohutova , Veronika Moravcova , Ondrej Zidek , Pavlina Prochazkova , Vladimir Velebny

IPC分类号： C08B37/00 , C08J3/24 , A61K47/36 , A61L27/20 , A61K47/61 , A61L27/52 , C08B37/08 , A61K31/198 , A61K38/06

CPC分类号： C08B37/0069 , A61K31/198 , A61K38/06 , A61K47/36 , A61K47/61 , A61L27/20 , A61L27/52 , C08B37/0042 , C08B37/0072 , C08G81/00 , C08J3/24 , C08J2305/00 , C08J2305/08

摘要： The invention relates to the preparation and the use of α,β-unsaturated aldehydes in the structure of sulfated polysaccharides. It concerns the derivatives with a conjugated double bond in the 4th and 5th positions of the galactopyranose part situated in the 6th position with respect to the aldehyde, according to the general structural formula (I) or its hydrated form according to the general structural formula (II). The preparation of these derivatives derives from sulfated polysaccharides containing a galactopyranose ring sulfated in the 4th position that is bound in the polymer chain via α(1→3) or β(1→3) O-glycosidic bond. In the described solution, the sulfated polysaccharides undergo a regio- and chemoselective oxidation to form C6-saturated aldehyde, which, via a direct elimination of the sulfate group, provides the α,β-unsaturated derivative according to the general formula (I) or (II). The described solution is technically advantageous, because it leads directly to α,β-unsaturated aldehydes, without any elimination agents, higher temperature, or isolation of intermediates during the synthesis. The conjugation in the structure of α,β-unsaturated aldehyde allows, under physiological conditions, to bind a wide variety of biocompatible amines in the structure of the sulfated polysaccharides. The proposed method allows to prepare materials suitable for pH-responsive drug delivery systems, or for the preparation of scaffolds in tissue engineering or regenerative medicine. Formulae for the abstract (I), (II) above, where R is OH, O—SO2—OH, O—SO2—ONa, or NH—Ac.

38.

发明申请
Cosmetic Method and Dermatological Topical Agent for Use Therein, Migration Imparting Agent, and Method for Screening Components for Use in Cosmetic Method for Improving Skin State 审中-公开

公开(公告)号：US20180161262A1

公开(公告)日：2018-06-14

申请号：US15577552

申请日：2016-05-26

申请人： ROHTO PHARMACEUTICAL CO., LTD.

发明人： Tomohiro Tsuda , Masayo Yumoto

IPC分类号： A61K8/65 , A61Q19/00 , A61K8/64 , A61K8/34 , G01N33/50

CPC分类号： A61K8/65 , A61K8/345 , A61K8/64 , A61K38/06 , A61K38/07 , A61K2800/592 , A61K2800/78 , A61Q19/00 , G01N33/502 , G01N33/5029 , G01N33/5073

摘要： The present invention relates to a cosmetic method comprising applying a migration imparting agent for adipose-derived stem cells to the skin, thereby allowing adipose-derived stem cells to migrate to the dermal layer and improving a skin condition. The present invention also relates to an external skin preparation for use in the cosmetic method, the external skin preparation comprising a migration imparting agent allowing adipose-derived stem cells to migrate to the dermal layer by application to the skin. The present invention further relates to a migration imparting agent for adipose-derived stem cells, comprising at least one of a polyol compound and a hydrophilic biomaterial. The present invention further relates to a method of screening for a component for use in a cosmetic method for improving a skin condition, comprising evaluating migratory activity of adipose-derived stem cells by using a prepared medium containing a sample.